| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Stefan Leucht | |
| Anne Karow | |||
| Dieter Naber | |||
| Martin Lambert | |||
| Benno G. Schimmelmann | |||
| P2860 | cites work | A systematic review of longitudinal outcome studies of first-episode psychosis | Q22251390 |
| Statistical validation of the criteria for symptom remission in schizophrenia: preliminary findings | Q33291585 | ||
| Remission in schizophrenia: proposed criteria and rationale for consensus | Q33985442 | ||
| Testing definitions of symptom remission in first-episode psychosis for prediction of functional outcome at 2 years | Q34092686 | ||
| Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. | Q34302194 | ||
| Standardized remission criteria in schizophrenia. | Q34486075 | ||
| Comparative remission rates of schizophrenic patients using various remission criteria | Q34794487 | ||
| Improving patient outcomes in schizophrenia: achieving remission | Q36626254 | ||
| Correlates and long-term consequences of poor insight in patients with schizophrenia. A systematic review | Q36731884 | ||
| Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders | Q36774833 | ||
| Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics | Q36853291 | ||
| Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study | Q37031581 | ||
| Predictors of psychosis remission in psychotic disorders that co-occur with substance use | Q37075954 | ||
| Predictors of long-term outcome in schizophrenia | Q37107017 | ||
| Clinical recovery in first-episode psychosis | Q37137014 | ||
| Outcome among community dwelling older adults with schizophrenia: results using five conceptual models | Q37267369 | ||
| Definitions of response and remission in schizophrenia: recommendations for their use and their presentation | Q37365409 | ||
| Predictors of 10-year outcome of first-episode psychosis | Q37383638 | ||
| The importance of cross-sectional remission in schizophrenia for long-term outcome: a clinical prospective study. | Q37576744 | ||
| Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: prevalence and associations in a cross-sectional study. | Q40168969 | ||
| Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment | Q43238492 | ||
| Early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride | Q43238914 | ||
| Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). | Q43264112 | ||
| Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder | Q43269342 | ||
| Remission in schizophrenia: analysis in a naturalistic setting | Q43657736 | ||
| Rate and predictors of service disengagement in an epidemiological first-episode psychosis cohort | Q44008161 | ||
| Predictors of remission and recovery in a first-episode schizophrenia spectrum disorder sample: 2-year follow-up of the OPUS trial | Q44221972 | ||
| Atypical and Conventional Antipsychotic Drugs in Treatment-Naive First-Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine Vs Chlorpromazine | Q44407173 | ||
| Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia | Q44450972 | ||
| Symptom remission in first episode patients | Q44699777 | ||
| Remission in schizophrenia: results from a 1-year follow-up observational study. | Q45221315 | ||
| Remission in the outpatient care of schizophrenia: 3-year results from the Schizophrenia Outpatients Health Outcomes (SOHO) study in France | Q45713492 | ||
| Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. | Q45905276 | ||
| Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates. | Q46178019 | ||
| Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection | Q46502498 | ||
| A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia | Q46627223 | ||
| Direct transition to long-acting risperidone--analysis of long-term efficacy | Q46689236 | ||
| A multi-site Canadian perspective: examining the functional outcome from first-episode psychosis | Q46942854 | ||
| Predictors of employment for people with severe mental illness: results of an international six-centre randomised controlled trial | Q48357010 | ||
| Remission as perceived by people with schizophrenia, family members and psychiatrists | Q48669705 | ||
| Recovery from schizophrenia: results from a 1-year follow-up observational study of patients in symptomatic remission. | Q51863887 | ||
| Association between symptomatic remission and functional outcome in first-episode schizophrenia. | Q51876786 | ||
| Predictors of outcome in first-episode schizophrenia over the first 4 years of illness. | Q51891293 | ||
| One-year outcome and its prediction in first-episode schizophrenia--a naturalistic study. | Q51896419 | ||
| On the concept of remission in schizophrenia. | Q51901729 | ||
| Predictors of service disengagement in first-admitted adolescents with psychosis. | Q51914433 | ||
| Diagnostic stability 18 months after treatment initiation for first-episode psychosis. | Q51924630 | ||
| Beyond the critical period: longitudinal study of 8-year outcome in first-episode non-affective psychosis. | Q51943357 | ||
| Remission and cognitive ability in a cohort of patients with schizophrenia. | Q51979493 | ||
| Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. | Q53211235 | ||
| Validation of remission criteria for schizophrenia. | Q53220574 | ||
| Schizophrenia | Q55868331 | ||
| Predicting Recovery From Schizophrenia: A Retrospective Comparison of Characteristics at Onset of People With Single and Multiple Episodes | Q57413695 | ||
| Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study | Q57709401 | ||
| Remission in schizophrenia: Applying recent consensus criteria to refine the concept | Q60636303 | ||
| Predictive value of cognition for different domains of outcome in recent-onset schizophrenia | Q79399753 | ||
| Remission in first-episode psychosis: predictor variables and symptom improvement patterns | Q79463287 | ||
| Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride | Q79629317 | ||
| Remission criteria for schizophrenia: evaluation in a large naturalistic cohort | Q79869898 | ||
| Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes | Q79965732 | ||
| The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone | Q80327118 | ||
| Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks | Q80650775 | ||
| Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia | Q81692532 | ||
| Long-term patterns of subjective wellbeing in schizophrenia: cluster, predictors of cluster affiliation, and their relation to recovery criteria in 2842 patients followed over 3 years | Q82239654 | ||
| Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study | Q82723809 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported | Q19125045 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| schizophrenic psychology | Q69941090 | ||
| P304 | page(s) | 393-407 | |
| P577 | publication date | 2010-01-01 | |
| P1433 | published in | Dialogues in Clinical Neuroscience | Q24255736 |
| P1476 | title | Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later | |
| P478 | volume | 12 |
| Q53894295 | A naturalistic study on the relationship among resilient factors, psychiatric symptoms, and psychosocial functioning in a sample of residential patients with psychosis. |
| Q36234891 | Assessment of functioning in patients with schizophrenia and schizoaffective disorder with the Mini-ICF-APP: a validation study in Italy |
| Q57039699 | Baseline brain structural and functional predictors of clinical outcome in the early course of schizophrenia |
| Q33577212 | Caregiver's quality of life and its positive impact on symptomatology and quality of life of patients with schizophrenia |
| Q35096476 | Clinical Global Impression-severity score as a reliable measure for routine evaluation of remission in schizophrenia and schizoaffective disorders. |
| Q35109168 | Clinical predictors of therapeutic response to antipsychotics in schizophrenia |
| Q49590987 | Consensus five factor PANSS for evaluation of clinical remission: effects on functioning and cognitive performances |
| Q35057412 | Criteria for symptom remission revisited: a study of patients affected by schizophrenia and schizoaffective disorders |
| Q37554113 | Design and validation of standardized clinical and functional remission criteria in schizophrenia. |
| Q34531769 | Disturbed macro-connectivity in schizophrenia linked to oligodendrocyte dysfunction: from structural findings to molecules |
| Q41955208 | Does duration of untreated psychosis predict very long term outcome of schizophrenic disorders? results of a retrospective study |
| Q46337178 | FDG-PET scans in patients with Kraepelinian and non-Kraepelinian schizophrenia |
| Q41895956 | Factors Affecting Well-being and Socio-occupational Functioning in Schizophrenia Patients Following an Acute Exacerbation: A Hospital Based Observational Study |
| Q51731261 | Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics. |
| Q93377111 | Impaired introspective accuracy in schizophrenia: an independent predictor of functional outcomes |
| Q38396447 | Kraepelin revisited: schizophrenia from degeneration to failed regeneration. |
| Q34502693 | Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study |
| Q41899147 | Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). |
| Q92776112 | Mismatch Negativity Indices as a Prognostic Factor for Remission in Schizophrenia |
| Q64236153 | Mobile App-Based Intervention for Adolescents With First-Episode Psychosis: Study Protocol for a Pilot Randomized Controlled Trial |
| Q41578608 | Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate |
| Q43144675 | Neural substrate of quality of life in patients with schizophrenia: a magnetisation transfer imaging study |
| Q38180211 | Neurocognition: clinical and functional outcomes in schizophrenia |
| Q38908382 | Neuropsychological correlates of remission in chronic schizophrenia subjects: The role of general and task-specific executive processes. |
| Q91887412 | Perspectives of patients, carers and mental health staff on early warning signs of relapse in psychosis: a qualitative investigation |
| Q37280123 | Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis |
| Q36072624 | Predicting functional remission in patients with schizophrenia: a cross-sectional study of symptomatic remission, psychosocial remission, functioning, and clinical outcome |
| Q64063169 | Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation |
| Q35753466 | Remission in schizophrenia: results of cross-sectional with 6-month follow-up period and 1-year observational therapeutic studies in an outpatient population |
| Q37300932 | Remission, response, and relapse rates in patients with acute schizophrenia treated with olanzapine monotherapy or other atypical antipsychotic monotherapy: 12-month prospective observational study |
| Q38979325 | The SWITCH study: rationale and design of the trial. |
| Q34074662 | The assessment of quality of life in clinical practice in patients with schizophrenia |
| Q42791247 | The importance of measuring psychosocial functioning in schizophrenia. |
| Q39269381 | The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. |
| Q92549284 | The interplay among psychopathology, personal resources, context-related factors and real-life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and non-recovered patients |
| Q35370032 | The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics |
| Q37111828 | The personal, societal, and economic burden of schizophrenia in the People's Republic of China: implications for antipsychotic therapy |
| Q34274631 | Towards a framework for treatment effectiveness in schizophrenia. |
| Q39245331 | Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studies. |
| Q50620570 | What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial. |
Search more.